Therefore, in this study, we detected PSA1M for patients who underwent RARP and calculated the PSA decline rate in the first month (PSADR1M = postoperative PSA in the first month/initial PSA), which is a comprehensive value that compares the preoperative and postoperative tumor burden and can reflect the risk of residual tumors more sensitively. This evidence concerns the gene KLK3 and neoplasm.